Search
Fate Therapeutics Inc
FATEAdd to Watchlist
2.100USD
+0.230+12.30%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
242.26MMarket Cap
LossP/E TTM
More Details of Fate Therapeutics Inc Company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Fate Therapeutics Inc Info
Ticker SymbolFATE
Company nameFate Therapeutics Inc
IPO dateOct 01, 2013
CEOValamehr (Bahram)
Number of employees181
Security typeOrdinary Share
Fiscal year-endOct 01
Address12278 Scripps Summit Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92131
Phone18588751803
Websitehttps://fatetherapeutics.com/
Ticker SymbolFATE
IPO dateOct 01, 2013
CEOValamehr (Bahram)
Company Executives of Fate Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
642.42K
+3.89%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
239.70K
+58.86%
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
64.80K
-44.67%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
36.33K
+68.81%
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Independent Director
Independent Director
--
--
Mr. Kamal Adawi
Mr. Kamal Adawi
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
642.42K
+3.89%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
239.70K
+58.86%
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
64.80K
-44.67%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
36.33K
+68.81%
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
FAQs
Who are the top five shareholders of Fate Therapeutics Inc?
The top five shareholders of Fate Therapeutics Inc are: Dr. William H. (Bill) Rastetter, Ph.D.
How many institutions hold shares of Fate Therapeutics Inc (FATE)?
As of 2026Q1, 379 institutions hold shares of Fate Therapeutics Inc, with a combined market value of approximately 92.31M, accounting for 79.47% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -39055587.00.
